Insulin glargine use and short-term incidence of malignancies — a three-year population-based observation

References

• Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdottir S, Steineck G. Insulin glargine use and short-term incidence of malignancies – a population-based follow-up study in Sweden. Diabetologia 2009;52:1745–54.
   PubMed Web of Science ®Google Scholar
• Colhoun HM. Use of insulin glargine and cancer incidence in Scotland: A study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 2009;52:1755–65.
   PubMed Web of Science ®Google Scholar
• Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52:1766–77.
   PubMed Web of Science ®Google Scholar
• Hemkens LG, Grouven U, Bender R, Gunster C, Gutschmidt S, Selke GW, . Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: A cohort study. Diabetologia 2009;52:1732–44.
   PubMed Web of Science ®Google Scholar
• Home PD, Lagarenne P. Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 2009;52:2499–506.
   PubMed Web of Science ®Google Scholar
• Mannucci E, Monami M, Balzi D, Cresci B, Pala L, Melani C, . Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 2010.
   Google Scholar
• Hernandez-Diaz S, Adami HO. Diabetes therapy and cancer risk: Causal effects and other plausible explanations. Diabetologia 2010;53:802–8.
   PubMed Web of Science ®Google Scholar
• Renehan A, Smith U, Kirkman MS. Linking diabetes and cancer: A consensus on complexity. Lancet 2010;375:2201–2.
   PubMed Web of Science ®Google Scholar
• Smith U, Gale EA. Cancer and diabetes: Are we ready for prime time? Diabetologia 2010;53:1541–4.
   PubMed Web of Science ®Google Scholar
• Wettermark B, Hammar N, Ford CM, Leimanis A, Otterblad Olausson P, Bergman U, . The new Swedish Prescribed Drug Register – opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007;16:726–35.
   PubMed Web of Science ®Google Scholar
• Barlow L, Westergren K, Holmberg L, Talbäck M. The completeness of the Swedish Cancer Register: A sample survey for year 1998. Acta Oncol 2009;48:27–33.
   PubMed Web of Science ®Google Scholar
• WHO Collaboration Centre for Drugs Statistics Methodology. Available from: http://www.whocc.no/atcddd/. Accessed 2010 Feb 10.
   Google Scholar
• Keay SD, Liversedge NH, Akande VA, Mathur RS, Jenkins JM. Serum IGF-1 concentrations following pituitary desensitization do not predict the ovarian response to gonadotrophin stimulation prior to IVF. Hum Reprod 2003;18:1797–801.
   Google Scholar
• Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, . Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000;49:2142–8.
   PubMed Web of Science ®Google Scholar
• Strasburger CJ, Bidlingmaier M, Wu Z, Morrison KM. Normal values of insulin-like growth factor I and their clinical utility in adults. Horm Res 2001;55(Suppl 2):100–5.
   Google Scholar
• Mayer D, Shukla A, Enzmann H. Proliferative effects of insulin analogues on mammary epithelial cells. Arch Physiol Biochem 2008;114:38–44.
   PubMedGoogle Scholar
• Shukla A, Grisouard J, Ehemann V, Hermani A, Enzmann H, Mayer D. Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines. Endocr Relat Cancer 2009; 16:429–41.
   PubMed Web of Science ®Google Scholar
• Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H. Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes Metab Res Rev 2009;25:41–9.
   PubMed Web of Science ®Google Scholar
• Agin A, Jeandidier N, Gasser F, Grucker D, Sapin R. Glargine blood biotransformation: In vitro appraisal with human insulin immunoassay. Diabetes Metab 2007; 33:205–12.
   PubMed Web of Science ®Google Scholar
• Mayer D, Chantelau E. Treatment with insulin glargine (Lantus) increases the proliferative potency of the serum of patients with type-1 diabetes: A pilot study on MCF-7 breast cancer cells. Arch Physiol Biochem 2010; 116:73–8.
   PubMedGoogle Scholar
• Butler PC. Insulin glargine controversy: A tribute to the editorial team at Diabetologia. Diabetes 2009;58: 2427–8.
   PubMed Web of Science ®Google Scholar
• Gale EA. Insulin glargine and cancer: Another side to the story? Lancet 2009;374:521.
   PubMed Web of Science ®Google Scholar
• Pocock SJ, Smeeth L. Insulin glargine and malignancy: An unwarranted alarm. Lancet 2009;374:511–3.
   PubMed Web of Science ®Google Scholar
• Smith U, Gale EA. Does diabetes therapy influence the risk of cancer? Diabetologia 2009;52:1699–708.
   PubMed Web of Science ®Google Scholar